154 related articles for article (PubMed ID: 29540677)
1. SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.
Nestal de Moraes G; Ji Z; Fan LY; Yao S; Zona S; Sharrocks AD; Lam EW
Oncogenesis; 2018 Mar; 7(3):29. PubMed ID: 29540677
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.
Nestal de Moraes G; Khongkow P; Gong C; Yao S; Gomes AR; Ji Z; Kandola N; Delbue D; Man EP; Khoo US; Sharrocks AD; Lam EW
Oncogenesis; 2015 Sep; 4(9):e167. PubMed ID: 26344694
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells.
Alasiri G; Jiramongkol Y; Zona S; Fan LY; Mahmud Z; Gong G; Lee HJ; Lam EW
Oncogene; 2019 Sep; 38(36):6382-6398. PubMed ID: 31312024
[TBL] [Abstract][Full Text] [Related]
4. FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
Liu Y; Ao X; Jia Z; Bai XY; Xu Z; Hu G; Jiang X; Chen M; Wu H
Sci Rep; 2015 Mar; 5():8796. PubMed ID: 25740706
[TBL] [Abstract][Full Text] [Related]
5. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
[TBL] [Abstract][Full Text] [Related]
6. FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis.
Li Y; Chen J; Wang B; Xu Z; Wu C; Ma J; Song Q; Geng Q; Yu J; Pei H; Yao Y
Drug Resist Updat; 2023 Mar; 67():100926. PubMed ID: 36682222
[TBL] [Abstract][Full Text] [Related]
7.
Yu Y; Cao WM; Cheng F; Shi Z; Han L; Yi JL; da Silva EM; Dopeso H; Chen H; Yang J; Wang X; Zhang C; Zhang H
bioRxiv; 2023 May; ():. PubMed ID: 37398114
[TBL] [Abstract][Full Text] [Related]
8. FOXK2 transcription factor and its roles in tumorigenesis (Review).
Wang Z; Liu X; Wang Z; Hu Z
Oncol Lett; 2022 Dec; 24(6):461. PubMed ID: 36380871
[TBL] [Abstract][Full Text] [Related]
9. Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation.
Qian Y; Xia S; Feng Z
Biochem Biophys Res Commun; 2017 Jan; 483(1):475-481. PubMed ID: 28007600
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival.
Alasiri G; Jiramongkol Y; Trakansuebkul S; Ke HL; Mahmud Z; Intuyod K; Lam EW
Mol Cell Endocrinol; 2020 Sep; 515():110932. PubMed ID: 32615282
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
Gong C; Yao S; Gomes AR; Man EP; Lee HJ; Gong G; Chang S; Kim SB; Fujino K; Kim SW; Park SK; Lee JW; Lee MH; ; Khoo US; Lam EW
Oncogenesis; 2016 Apr; 5(4):e214. PubMed ID: 27043660
[TBL] [Abstract][Full Text] [Related]
12. Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes.
Chen S; Jiang S; Hu F; Xu Y; Wang T; Mei Q
Oncol Rep; 2017 Apr; 37(4):2335-2347. PubMed ID: 28260088
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation inhibits FOXM1 activity and delays mitotic transition.
Myatt SS; Kongsema M; Man CW; Kelly DJ; Gomes AR; Khongkow P; Karunarathna U; Zona S; Langer JK; Dunsby CW; Coombes RC; French PM; Brosens JJ; Lam EW
Oncogene; 2014 Aug; 33(34):4316-29. PubMed ID: 24362530
[TBL] [Abstract][Full Text] [Related]
14. PPARγ gene expression is autoregulated in primary adipocytes: ligand, sumoylation, and isoform specificity.
Armoni M; Harel C; Karnieli E
Horm Metab Res; 2015 Feb; 47(2):89-96. PubMed ID: 25409419
[TBL] [Abstract][Full Text] [Related]
15. FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.
Zhang F; Ma X; Li H; Zhang Y; Li X; Chen L; Guo G; Gao Y; Gu L; Xie Y; Duan J; Zhang X
Int J Cancer; 2018 Jun; 142(12):2543-2557. PubMed ID: 29368368
[TBL] [Abstract][Full Text] [Related]
16. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
[TBL] [Abstract][Full Text] [Related]
17. FOXK2 Transcription Factor and Its Emerging Roles in Cancer.
Nestal de Moraes G; Carneiro LDT; Maia RC; Lam EW; Sharrocks AD
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897782
[TBL] [Abstract][Full Text] [Related]
18. FOXK2 targeting by the SCF-E3 ligase subunit FBXO24 for ubiquitin mediated degradation modulates mitochondrial respiration.
El-Mergawy R; Chafin L; Ovando-Ricardez JA; Rosa L; Tsai M; Rojas M; Mora AL; Mallampalli RK
J Biol Chem; 2024 May; ():107359. PubMed ID: 38735474
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.
Aimjongjun S; Mahmud Z; Jiramongkol Y; Alasiri G; Yao S; Yagüe E; Janvilisri T; Lam EW
BMC Cancer; 2019 Nov; 19(1):1106. PubMed ID: 31727006
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA tumor protein 53 target gene 1 promotes cervical cancer development via regulating microRNA-33a-5p to target forkhead box K2.
Liao D; Liu X; Yuan X; Feng P; Ouyang Z; Liu Y; Li C
Cell Cycle; 2022; 21(6):572-584. PubMed ID: 35090377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
